MEDTOX Scientific Announces Third Quarter Results

ST. PAUL, Minn., Oct. 14, 2009 (GLOBE NEWSWIRE) -- MEDTOX Scientific, Inc. (Nasdaq:MTOX - News) today announced results for the third quarter ended September 30, 2009. For the three-month period, revenues were $22.3 million, compared to $22.4 million for the prior-year period. The Company recorded operating income of $1.0 million for the three-month period, compared to $2.8 million for the prior-year period. The Company recorded net income of $0.8 million for the three-month period, compared to $1.6 million for the prior-year period. Earnings per diluted share were $0.09, compared to $0.19 in the third quarter of 2008. For the nine-month period ended September 30, 2009, revenues were $64.3 million, compared to $65.0 million from the prior-year period. Operating income was $2.5 million, compared to $8.6 million for the prior-year period. The Company recorded net income of $1.5 million, compared to $5.2 million for the prior-year period. Earnings per diluted share were $0.17, compared to $0.58 for the prior-year period. For the three-month period, in our Laboratory Segment, revenues from drugs-of-abuse (DAU) testing decreased a net 9.0%, to $9.5 million from $10.4 million in the prior-year period. The decrease is a result of lower testing volumes from our workplace clients due to economic conditions. Revenues from existing workplace clients were $7.9 million, down 23.8% for the quarter compared to the prior-year period. The decrease in revenue was mitigated by very strong business from new DAU lab...
Click here to read the whole Article (external link)

MEDTOX Scientific Inc. Q3 2009 Earnings Call Transcript

MEDTOX Scientific Inc. (MTOX) Q3 2009 Earnings Call October 14, 2009; 10:30 am ET Executives Dick Braun - Chief Executive Officer Ken Wiersma - Chief Financial Officer James Schoonover - Chief Marketing Officer Analysts Steven Crowley - Craig-Hallum Capital Group Presentation Operator Good day everyone and welcome to the MEDTOX quarterly conference call. Today’s conference is being recorded and now it is my pleasure to turn the conference over to Mr. Ken Wiersma, Chief Financial Officer. Please go ahead sir. Ken Wiersma Good morning everyone. I am Kevin Wiersma, Chief Operating Officer in the MEDTOX Laboratory Services Division, and also CFO of the company. Welcome to our third quarter conference call. Before Dick Braun, our CEO, begins our prepared presentation, I’d like to cover one administrative item. Forward-looking statements in our conference call today are made under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Any such statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated. Such factors are described from time-to-time in the company’s Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Our call today is in listen-only mode, and we'd also like to welcome those listeners who have accessed this morning's call on the Internet. Following our prepared remarks, we'll have a question-and-answer session that’s accessible to institutional investors and qualified financial analysts covering MEDTOX and our industry. We look forward to your questions. Also joining us for our call is Jim Schoonover, our Chief Marketing Offi...
Click here to read the whole Article (external link)

MEDTOX Scientific, Inc. Earnings Call scheduled for 10:30 am ET today

Call DetailsMEDTOX Scientific, Inc. Earnings Conference Call (Q3 2009)Wed, Oct 14, 2009, 10:30 am EasternAbout MEDTOX Scientific, Inc. (NasdaqGS:MTOX)MEDTOX Scientific, Inc. and its subsidiaries provide forensic and clinical laboratory services. It also manufactures and distributes diagnostic and related devices. The Laboratory Services segment offers workplace drug-of-abuse testing services. Its services include pediatric lead testing; heavy metal, trace element, and solvent analyses; logistical support, data management, and program management, such as courier services for medical specimen transportation, management programs for laboratory-based and on-site drug testing, coordination of specimen collection sites, and data collection/reporting; and pain management. This segment also offers forensic and clinical toxicology services; clinical testing for occupational health clinics and physician offices; and clinical testing for the pharmaceutical industry, such as general and central laboratory services, assay/test development, bio-analytical, and pharmacokinetic testing for clinical trial sponsors, clinical research organizations, and site management organizations. The Product Sales segment offers point-of-collection testing (POCT) products for drug abuse. It offers diagnostic drug screening products, such as PROFILE-II ER and PROFILE-III ER, and PROFILE-IV to hospital markets for drug detection in the hospital and emergency rooms; MEDTOXScan, an electronic reader for use with PROFILE-V MEDTOXScan device in hospital laboratories and emergency rooms; and VERDICT-II and SURE-SCREEN diagnostic drug screening products for criminal justice and drug rehabilitation markets. This segment also offers coagulation/blood clotting market controls; and distributes diagnostic tests for the detection of alcohol with the EZ-SCREEN Breath Alcohol Test. The company serves ...
Click here to read the whole Article (external link)

Q3 2009 MEDTOX Scientific, Inc. Earnings Release - Before Market Open

Earnings Announcements for Wednesday, October 14CompanySymbolTimeConferenceCallAbbottABTBefore Market OpenAcergy S.A.ACGYTime Not SuppliedListenAIR PARTNERAIP.LBefore Market OpenAlliance FinancialALNCAfter Market CloseAptarGroupATRAfter Market CloseListenASML Holdings NVASML01:00 am ETBASFBASFY.PKTime Not SuppliedCommerce Bancshares, Inc.CBSHBefore Market OpenCONTAINER CORPN OF INDIA LTDCONCOR.BOTime Not SuppliedCROPENERGIES AG MANNHEIMCE2.F01:00 am ETCrown Holdings, Inc.CCKAfter Market CloseListenDATA RESPONS ASADAT.OL02:30 am ETDatalink Corp.DTLKAfter Market CloseListenDIP CORP TOKYODPRTF.PKAfter Market CloseEnzo BiochemENZAfter Market CloseGenerex Biotechnology CorporationGNBTAfter Market CloseGOODPACK LTDG05.SIAfter Market Close...
Click here to read the whole Article (external link)

MEDTOX SCIENTIFIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh

Show all filings for MEDTOX SCIENTIFIC INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for MEDTOX SCIENTIFIC INC 20-Oct-2009Results of Operations and Financial Condition, Financial Statements and Exh Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information prov...
Click here to read the whole Article (external link)

MEDTOX SCIENTIFIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh

Show all filings for MEDTOX SCIENTIFIC INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for MEDTOX SCIENTIFIC INC 16-Oct-2009Results of Operations and Financial Condition, Financial Statements and Exh Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information prov...
Click here to read the whole Article (external link)

New Star Analyst Rankings for Medtox Scientific, Inc.

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Copyright © 1999-2003, StarMine Corp. All rights reserved.StarMine Corp. derives analyst ratings from estimate and recommendation data supplied by Thomson Financial.Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). International historical chart data, daily updates, fund summary, fund performance, dividend data and...
Click here to read the whole Article (external link)

MEDTOX SCIENTIFIC INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Show all filings for MEDTOX SCIENTIFIC INC | Request a Trial to NEW EDGAR Online Pro Form 8-K for MEDTOX SCIENTIFIC INC 5-Nov-2009Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information p...
Click here to read the whole Article (external link)

MEDTOX SCIENTIFIC INC Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue22,261  21,332  20,658  20,821  Cost of Revenue13,575  13,666  13,015  12,598  Gross Profit8,686  7,666  7,643  8,223  Operating ExpensesResearch Development555  589  570  634  Selling General and Administrative7,084  6,521  6,221  6,529  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss1,047  556  852  1,060  Income from Continuing OperationsTotal Other Income/Expenses Net151  (62)(184)(382)Earnings Before Interest And Taxes1,198  494  668  678  Interest Expense4  5  6  10  Income Before Tax1,194  489  662  668  Income Tax Expense436  178  242  255  Minority Interest -   -   -   -  Net Income From Continuing Ops758  311  420  413  Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   ...
Click here to read the whole Article (external link)

MEDTOX SCIENTIFIC INC Files SEC form 10-Q, Quarterly Report

Item 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Form 10-Q contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created by such acts. For this purpose, any statements that are not statements of historical fact may be deemed to be forward looking statements, including the statements under "Management's Discussion and Analysis of Financial Condition and Results of Operations" regarding our strategy, future operations, future expectations and future estimates, future financial position or results, and future plans and objectives of management. Those statements in this Form 10-Q containing the words "believes", "anticipates", "plans", "expects", and similar expressions constitute forward looking statements, although not all forward looking statements contain such identifying words. Examples of forward looking statements include, but are not limited to (i) projections of, or statements regarding, future revenues, income or loss, earnings or loss per share, capital expenditures, dividends, capital structure, margins and other financial items, (ii) statements regarding our plans and objectives and the impacts thereof, including planned introductions of new products and services, planned exiting of lines of business and planned regulatory filings, or estimates or predictions of actions by customers, suppliers, competitors or regulatory authorities, (iii) estimates of market sizes and market opportunities, (iv) statements regarding economic conditions, (v)) statements regarding the sufficiency of our existing resources to fund our planned operations through 2009 and the sufficiency of future profitable operations and access to additional capital to fund our operations beyond 2009, and (vi) statements of assumptions underlyin...
Click here to read the whole Article (external link)